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ABSTRACT
Objective: The importance of SIRT1 activator’s role in antidiabetic and anti-aging therapies is widely demonstrated. Drug discovery and development 
are time consuming. Drug design can be performed in silico using molecular dynamic approaches to accelerate and facilitate identification of the best 
compound candidates and their physicochemical characteristics and hit-to-lead selection.
Methods: In silico study of SIRT1 activator for complexes using of Protein Data Bank (PDB) IDs 4ZZI, 4ZZJ 4ZZH, and 5BTR and 4TO ligand. Ligand–
receptor interactions and bond energies were determined using molecular docking with the AutoDock4Zn program. Then, the complex with the 
best bond energy was identified using a simulation of the molecular dynamics (50 ns) using the Amber program, and values for root mean square 
deviation, root mean square fluctuation, and bond energy were determined using the Molecular Mechanic–Poisson Boltzmann (Generalized Born) 
surface area (MM-PB[GB]SA) calculation.
Results: Interaction analysis between activator ligand (4TO) and the SIRT1 receptor (PDB IDs 4ZZJ and 5BTR) revealed the ligand’s selectivity for 
hydrophobic interaction at Leu206, Ile223, Ile227, and hydrophilic interaction at Asn226, Glu230. Hydrogen bond interactions between Glu230 and Arg234 
(allosteric region) with Arg446, Val459, His473, and Asp475 (catalytic region) brought them close to the bounding substrate area. Bond energy values 
obtained using the MM-GB(PB)SA calculation showed 4TO interaction with 4ZZJ (MMGBSA ∆G, −31.4729–−26.6756; MMPBSA ∆G, −32.6292–−28.486]. 
The bond energy value of the 4TO interaction with 5BTR showed MMGBSA ∆G = −40.6255–−30.0653 and MMPBSA ∆G = −34.6713–−25.9951.
Conclusions: These findings provide important information on the target interaction of the bonds to the more selective SIRT1 activator useful for 
drug discovery and development.
Keywords: SIRT1 activator, Molecular docking, Molecular dynamic, Molecular mechanic/Poisson Boltzmann (generalized born) surface area.
INTRODUCTION
SIRT1 enzyme activity has two primary roles as a target for therapy, namely 
SIRT1 inhibition in the catalytic region which is used in cancer treatment 
and SIRT1 activation in the allosteric region which is used in metabolic 
damage treatment, including diabetes [1,2] and anti-aging [3-5]. SIRT1 is a 
nicotinamide adenine dinucleotide (NAD+)-dependent deacetylase which 
catalyzes of deacetylating protein in lysine residues [6,7].
The structure of human sirtuin protein includes the SIRT1 isoform 
(UniProt accession code Q96EB6, available online: NCBI, Research 
Collaboratory for Structural Bioinformatics). The SIRT1 sequence 
comprises 747 amino acids; amino acids 1–180 are located at the 
N-terminal region, amino acids 195–240 in the allosteric region (active 
regulator of SIRT1), amino acids 244–512 in the catalytic region, and 
amino acids 513–747 in the C-terminal region [8].
Nucleotide bonds including NAD+ are found in the amino acid regions 
261–280, 345–348, 440–442, and 465–467; metal bonds are present 
at amino acids 371, 374, 395, and 398; the deacetylase area is at amino 
acids 244–498; and the activation area including sirtuin-activating 
compounds (STACs) are at amino acids 195–243 and Glu(E)230 [9,10]. 
Homologous sequences identical to SIRT1 and with allosteric regions 
obtained from the protein data bank (PDB) [6] include PDB IDs 4ZZI, 
4ZZJ, 4ZZH [11], and 5BTR [12].
The structure of SIRT1 PBD ID 4ZZI comprises a ligand activator 4TQ ([3S]-
1,3-dimethyl-N-[3-[1,3-oxazol-5-yl]phenyl]-6-[3-[trifluoromethyl]phenyl]-
2,3-dihydropyrido[2,3-b]pyrazine-4[1H]-carboxamide) that interacts at 
the allosteric region, and ligand inhibitor 1NS 4-(4-[2-[[methylsulfonyl]
amino]ethyl] piperidin-1-yl)thieno(3,2-d)pyrimidine-6-carboxamide in 
the catalytic region. 4TQ activators demonstrate hydrophobic interactions 
(HIs) at amino acids Thr219, Leu215, Ile223, and hydrogen bond at Asn226. 
The 1NS inhibitor shows HIs at residues Phe297 and His363 and hydrogen 
bonds at Phe273, Ile347, and Asp348.
The structure of SIRT1 PDB ID 4ZZJ (www.rcsb.org/structure/4ZZJ) 
shows interactions between 4TQ at the allosteric region of the HI of amino 
acids Thr219 and Ile223, hydrogen bonding at Asn226, and with CNA 
(carba-nicotinamide-adenine-dinucleotide) ligand at the catalytic region.
The active conformation model of SIRT1 comprises a STAC complex with 
the Ac–p53 substrate, indicating the presence of amino acid hydrogen 
bond interactions at Glu230 and Arg446. The structure of the complex 
of SIRT1 with STAC compounds shows binding of STAC-1 to the STAC 
binding domain (SBD). Binding of STAC encourages SBD interaction 
with the central catalytic region to the substrate, increasing the activity 
of SIRT1 and stabilizing the deacetylase activity. Replacement of Glu 
(E) 230 with Lys residue disrupts enzymatic activation by reducing the 
electrostatic interactions between Glu230 in the SBD and Arg446 at the 
substrate-binding site [13].
The structure of SIRT1 PDB ID 4ZZH (www. rcsb. org/structure/4ZZH) 
shows HIs of STACs (4TO) ([4S]-N-[3-[1,3-oxazol-5-yl]phenyl]-7-[3-
[trifluoromethyl] phenyl]-3,4-dihydro-1,4-methanopyrido[2,3-b][1,4]
diazepine-5[2H]-carboxamide) with Leu 215, Thr219, and ILE223 and 
hydrogen interactions with Asn226 in the allosteric region.
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The structure of SIRT1 PDB ID 5BTR (www.rcsb.org/structure/5btr) 
is the SIRT1 activator located in the allosteric region, a complex 
containing three resveratrol ligands (STL), and shows hydrogen 
bonding interactions at Gln222, Asn226, lys444, Asp298, Asp292, and 
Glu230 and HIs at Gly415, Ile223, Gln294, Ile223, and Arg446.
Interaction of 7-amino-4-methyl coumarin with 5BTR shows HIs at 
Phe412, Val445, His363, and Phe414 and hydrogen bond interactions 
at Arg446, Asn226, Gly415, Asp150, Glu416, and Val412 [12].
Therefore, the present study used an in silico study with molecular docking 
and dynamic simulations of the SIRT1 enzyme (PDB IDs 4ZZI, 4ZZJ, 4ZZH, 
and 5BTR) to determine the bonding interactions of SIRT1 required for 
ligand selectivity and selective identification of bond interactions and 
target bond interactions with biological function [14,15].
MATERIALS AND METHODS
Materials
The following materials were used: IntelXeon(R) central processing 
unit E5620 at 2.40 GHz × 16, processor 2.6 GHz Intel Core i7, random 
access memory 32 GB 1600 MHz DDR3, and Graphics Intel Iris 
1536 MB. The operating system used was Linux Ubuntu 12.04 LTS with 
an uninterrupted power supply.
Protein preparation
Preparation of macromolecular three-dimensional structure was 
done by downloading macromolecules SIRT1 (PDB IDs: 4ZZI, 4ZZJ, 
4ZZH, and 5BTR) was obtained from the Research Collaboratory for 
Structural Bioinformatics PDB (http://www. rscb. org/pdb) [16]. All 
macromolecules were clean-up from ligands, substrates, ions, and 
waters before minimization with Amber program [17].
Ligand preparation
The ligands used were the 4TO crystals of macromolecular SIRT1 (PDB 
IDs: 4ZZH). Minimization of ligand used the AMBER program, and 1NS 
compound (SIRT1 inhibitor) was used as a negative control.
Molecular docking validation
Autodock4Zn was used to perform molecular docking in this study [18,19]. 
Validation of the autodock4Zn program measured the root mean square 
deviation (RMSD) value analyzed using the visual molecular dynamics 
(VMD) program and the initial cocrystal structure of PDB against the 
conformational crystal positioning after molecular redocking was done.
Molecular docking
Molecular docking was performed using AutoDock4Zn, with ligand–
macromolecular grid binding sites by determining npts and gridcenter.
Analysis of the docking results in the form of affinity and RMSD binding 
values (for docking performance validation) and visualization of docking 
results to analyze ligand interaction with macromolecules used LigandScout 
(Inte:Ligand, Austria) [20] and CHIMERA (UCSF, USA), respectively [21].
Molecular dynamics
The best compounds for molecular docking were selected for the 
molecular dynamics study, and the simulation was performed using 
Amber12 [17] for 50 ns.
General amber force field (GAFF) was used for ligand preparation [13]. 
Ligands and macromolecules topologies and coordinates were created 
in a vacuum and explicit waters environment. At this stage, the 
ligand structure was provided with an AM1–bond charge correction 
charge [14] using Antechamber software (UCSF, USA) accessed via 
PuTTY. The file output was obtained in the form of *.mol2, and the 
antechamber result created a *.frcmod file.
Preparation of parameters and coordinates of macromolecule files 
containing Zn was performed online (http://mayoresearch. mayo.edu/
mayo/research/camdl/zinc_protein.cfm).
Preparation of peptide minimization (substrate) used parameters 
and coordinates of peptide-containing (NArg His Lys Lys Leu Met 
CPhe) macromolecular files [22]. Preparation for the formation of 
NAD+ used NAD+ as a cofactor with a positive charge. The creation 
of macromolecules with NAD+ required NAD+.lib, and NAD+.frcmod 
parameter files were obtained from Ross Walker, and the coordinates 
were altered using the coordinates of the NAD+ file associated 
with the macromolecules. Further complexes of ligand: Zn: NAD+: 
Macromolecules were used as topological and coordinate files with the 
addition of water molecules TIP3PBOX 12Å3, followed by minimization, 
heating, density, equilibration, and production.
Before continuing the dynamics simulation, verification of the system 
was balanced using the command “process_mdout. pl” to extract useful 
information from the output file: heat. out, density. out, and equil. out. 
A balanced system was seen from the temperature, density, and RMSD.
After the balanced system was observed, production was continued 
for 50 ns. The ptraj program from AmberTools and VMD was used 
to perform trajectory analysis of the molecular dynamic simulation 
results [15]. The parameters analyzed were RMSD and root mean 
square fluctuation (RMSF), and the hydrogen bond conditions were 
analyzed using VMD program. Hydrogen bonds with an occupancy 
of >50% of the overall data from the hydrogen bond analysis were 
selected. The distance between the donor and acceptor of the hydrogen 
bond was set at 3.0Å, and the cutoff angle was set at 60°. The Molecular 
Mechanic–Poisson Boltzmann (Generalized Born) surface area (MM-
PB[GB]SA) method was used to calculate the binding energy [23].
RESULTS AND DISCUSSION
The present study was performed by visualizing 4TO cocrystal 
interactions with SIRT1 macromolecules (SIRT1 PDB IDs 4ZZI, 4ZZJ, 
and 4ZZH) and one with three STLs (PDB ID 5BTR). Analysis of complex 
compound interactions (STACs) with SIRT1 activator receptors in 
the allosteric region was used to examine the bonding interactions 
that play an important role in ligand selectivity. Activator compounds 
act as sirtuin activators bound to the amino acid allosteric site at 
residues 183–243 and generally interact at the hydrophobic chains 
at Thr209, Pro211, Pro212, Leu215, Thr219, Ile223, and Ile227 at 
the shape of the (helix-turn-helix) amino acid and one hydrophilic 
interaction at Asn226 (Supplemental Fig. 1).
Visualization of macromolecular interactions with SIRT1 PDB IDs 
4ZZI, 4ZZJ, 4ZZH, and 5BTR showed differences in the position of the 
allosteric region receptors. Residues at Glu230–Asn241 showed a 
flexible helix shape. As Fig. 1 shows, the superimposition of SIRT1 PDB 
ID 4ZZI demonstrates a more closed form between the allosteric and 
catalytic regions, containing 4TO ligand crystals in the allosteric region 
and 1NS ligand crystals in the catalytic region. SIRT1 PDB ID 4ZZJ 
contains CNA and 4TO ligand crystals in the allosteric region, and the 
allosteric area form was catalytically more open than that of 4ZZI. PDB 
4ZZH showed an allosteric and catalytic form that was more open and 
contained only 4TO ligand crystals in the allosteric region. PDB 5BTR 
contained resveratrol compounds in the allosteric region adjacent to 
the catalytic region.
Validation of molecular docking
In the present study, AutoDock4Zn was used to visualize molecular 
docking. Validation of this Autodock program measured the RMSD 
value analyzed using the VMD program. The initial cocrystal PDB 
structure was analyzed against the conformational crystal positioning 
after molecular docking restarted. The RMSD values of 4TO as a crystal 
were 0.81Å, 0.79Å, and 0.89Å for 4ZZI, 4ZZJ, and 4ZZH, respectively.
Molecular docking of macromolecular 4ZZI
The macromolecule receptor of 4ZZI has ligand crystals in the 
catalytic region as an activator. This ligand was 4TO ([4S]-N-[3-[1,3-
oxazole-5-yl] phenyl]-7-[3-[trifluoromethyl] phenyl]-3,4-dihydro-1,4-
methanopyrido [2,3-b] [1,4] diazepine-5 [2H]-carboxamide) in the 
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allosteric region as an activator. The molecular docking results of the 
4TO obtained bond energy values of ∆G = −6.86 kcal/mol and a Ki value 
of 9.36 µM (predicted binding interaction).
Fig. 2 shows the 4TO ligand crystal compound interaction. 4TO bonded 
to the activating region of essential amino acids Ile223 and Ile227. The 
complex showed four hydrophobic features at amino acids namely 
Leu206 (HI), Thr219 (HI), Ile223 (HI), Ile227 (HI), Asn226 (hydrogen 
bond acceptor [HBA]), and Glu230. Docking of the 1NS compound 
(SIRT1 inhibitor) as a negative control on the allosteric region 
showed interactions at Thr219 (HBD) and Ile227 (HBD) and no HIs 
(Supplemental Fig. 2).
Molecular docking of macromolecular 4ZZJ
The AutodockZn program was used to analyze docking of the ligand 
crystal molecule and the active compound SIRT1 with 4ZZJ. The 
results obtained from the process showed a bond energy value 
of ∆G = −6.94 kcal/mol, a Ki value of 8.24 μM (predicted binding 
interaction), and the complex interaction of ligand and receptor bonds.
Fig. 3 shows 4TO compound interaction. The complexes demonstrate 
four hydrophobic features at amino acids namely Leu206 (HI), Thr209, 
Leu215 (HI), Thr219 (HI), Ile223 (HI), and Ile227 (HI) and show 
acceptor hydrogen bonding interactions (HBA) at Asn226. Docking 
of the 1NS compound (SIRT1 inhibitor) as a negative control on the 
allosteric region showed interactions at Gln222 (HBD) and Thr219 
(HBD) and no HIs (Supplemental Fig. 2).
Molecular docking of macromolecular 4ZZH
The AutodockZn program was used to generate molecular 
docking of the crystal ligand molecule and the active compound 
SIRT1 with 4ZZH. The results were obtained using a bond energy 
value of ∆G = −7.61 kcal/mol and Ki = 5.6 μM (predicted binding 
interactions).
The 4TO compound showed interactions with four hydrophobic 
features of the amino acids namely Leu206 (HI), Leu215, Thr219 (HI), 
Ile223 (HI), and Ile227 (HI) and showed acceptor hydrogen bonding 
interactions (HBA) at Thr209 (HI) residues.
4TO compound interaction with macromolecules is shown in Fig. 4, 
showing interaction with four hydrophobic features at amino acids 
namely Leu206 (HI), Thr209, Leu215 (HI), Thr219 (HI), Ile223 (HI), 
and Ile227 (HI).
Fig. 1: Visualization superimposition crystal structure of protein data bank (4ZZI, 4ZZJ, 4ZZH, and 5BTR) shows the flexibility of allosteric 
region
Fig. 2: (a) Molecular docking of 4TO:4ZZI at the allosteric region. (b) Visualization of 4TO:4ZZI complex interactions at Thr219, Ile223, 
Ile227, Asn226 (hydrogen bond acceptor), and Glu230 using the LigandScout program. (c) Visualization of the 4TO:4ZZI complex using a 
mesh surface image generated by CHIMERA (hydrophilic, blue; hydrophobic, orange)
a b c
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Molecular docking of macromolecular 5BTR
Molecular docking 4TO with 5BTR using the AutodockZn program 
was obtained using a bond energy value of ∆G = −13.1 kcal/mol and 
Ki = 2.51 × 10−4 μM (predicted binding interaction).
The 4TO ligand revealed bonds at the activating regions of essential 
amino acids Ile223 and Ile227. The complex showed hydrophobic 
features at amino acids namely Leu206 (HI), Thr219 (HI), Ile223 (HI), 
and Ile227 (HI) (Fig. 5). Docking of the 1NS compound (SIRT1 inhibitor) 
as a negative control on the allosteric region showed interactions at 
Leu206 (HBD) and no HIs (Supplemental Fig. 2).
Molecular dynamic simulation
Molecular dynamic simulation of 4TO compounds against 4ZZI, 4ZZJ, 
4ZZH, and 5BTR receptors was performed for 50 ns using the Amber 
program. Analysis of the dynamics simulation result was carried out 
considering RMSD, RMSF, and hydrogen bonding conditions, and the 
binding energy was calculated using the MMGB/PBSA method.
RMSD
Conformational changes of the 4TO compound during the simulation 
were seen from the RMSD values. The RMSD curve for 50 ns showed 
a change in the stability of the 4TO complex dynamic simulation that 
corresponded to 4ZZI, 4ZZJ, 4ZZH, and 5BTR receptors. In Fig. 6, the 
4TO:4ZZI, 4TO:4ZZJ, and 4TO:5BTR complexes showed an RMSD range 
of 2Å, whereas the 4TO:4ZZH complex had a RMSD range of 3Å.
RMSF
RMSF is the measure of the deviation between the atomic positions of 
each protein residue, i.e., the difference in fluctuations in the movement 
of each residue during the simulation is measured for 50 ns. Fig. 7 
shows the RMSF value of the complex molecular dynamic simulation 
between the 4TO ligand (ligand crystal) and 4ZZI, 4ZZJ, 4ZZH, and 5BTR 
receptors. The 4ZZH receptor showed fluctuations of movement in the 
N-terminal domain of all RMSF compared with 4ZZI, 4ZZJ, and 5BTR 
receptors that did not show fluctuations, indicating that binding of the 
4TO compound to the receptor is more stable.
Fig. 3: (a) Molecular docking of 4TO to 4ZZJ at the allosteric region. (b) Visualization of 4TO:4ZZJ complex interactions at Leu206 
(hydrophobic interaction), Thr209, Leu215 (hydrophobic interaction), Thr219 (hydrophobic interaction), Ile223 (hydrophobic 
interaction), Ile227 (hydrophobic interaction), and Asn226 (hydrogen bond acceptor) using the LigandScout program. (c) Visualization of 
the 4TO:4ZZJ complex using a mesh surface image generated by CHIMERA (hydrophilic, blue; hydrophobic, orange)
a b c
Fig. 4: (a) Molecular docking of 4TO compound with protein data bank 4ZZH at the allosteric region. (b) Visualization of 4TO:4ZZH 
complex interactions at amino acids Leu206 (hydrophobic interaction), Thr209, Leu215 (hydrophobic interaction), Thr219 (hydrophobic 
interaction), Ile223 (hydrophobic interaction), and Ile227 (hydrophobic interaction) using the LigandScout program. (c) Visualization of 
4TO:4ZZH complex using a mesh surface image generated by CHIMERA (hydrophilic, blue; hydrophobic, orange)
a b c
Fig. 5: (a) Molecular docking of compound 4TO:5BTR at the allosteric region. (b) Visualization of 4TO:5BTR complex interactions at 
Leu206, Thr209 (hydrogen bond acceptor), Leu215 (hydrophobic interaction), Thr219 (hydrophobic interaction), Ile223 (hydrophobic 
interaction), and Ile227 (hydrophobic interaction) using the LigandScout program. (c) Visualization of 4TO–5BTR complex using a mesh 
surface image generated by CHIMERA (hydrophilic, blue; hydrophobic, orange)
a b c
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Fig. 6: Root mean square deviation and conformational changes of receptor structure at an interval of 10 ns (a). Zn:4ZZI, (b). peptide: 
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Fig. 8 shows the RMSF of the backbone atom in a dynamic simulation 
system between 4TO ligands with 4ZZI, 4ZZJ, 4ZZH, and 5BTR receptors 
for 50 ns in allosteric regions. The 4TO ligand bond with the 4ZZI 
receptor and 5BTR on Leu206, Leu215, Thr219, Ile223, Asn226, Ile227, 
and Glu230 residues did not show fluctuations (low RMSF values), 
indicating that binding occurred in the residue. These data correspond 
to the bonding interaction in ligand crystals 4ZZI [7] and 5BTR [8]. 
The bond interaction between the 4TO ligand and the 4ZZJ receptor 
shows a low RMSF value at Leu206, Ile223, Asn226 Ile227, and Glu230, 
demonstrating strong binding to the residue. These data correspond 
to the bonding interaction of the 4ZZJ ligand crystal [7]. The binding 
interaction between the 4TO ligand and the 4ZZH receptor shows high 
RMSF values at Ile223, Asn226, Ile227, and Glu230, showing no strong 
binding of such residues, as in the crystal ligands of 4ZZH [7].
Hydrogen bond analysis
As an activator of SIRT1 PDB ID 4ZZJ, the 4TO ligand crystal shows the 
presence of hydrogen bond interactions at Arg234–Asp475 (NH–O) 
2.83Å, Arg234–His473 (NH–O) 2.84Å, and Arg234–Val459 (NH–O) 3.01 
Å [7]. The VMD program was used to perform hydrogen bond strength 
analysis (% occupancy) of 4TO with SIRT1 PDB IDs 4ZZI, 4ZZJ, 4ZZH, 
and 5BTR from molecular dynamic simulations for 50 ns. Based on 
the molecular dynamic simulations, 4TO in complex with 4ZZ1 and 
4ZZH receptors did not show any hydrogen bond interactions between 
Glu230 (allosteric regions) and Arg446 (catalytic regions).
Fig. 9 shows the binding of 4TO ligand to the allosteric region but not to 
the activator of SIRT1.
The results of the hydrogen bond strength (% occupancy) in the complex 
of the 4TO ligand with 4ZZJ receptor indicated the presence of important 
amino acid interactions, namely Glu230–Arg446, 51%; Arg234–Asp475, 
65.1%; Arg234–His473, 22.50%; and Arg234–Val459, 11.7%. The 
hydrogen bond strength (% occupancy) in the complex of the 4TO 
ligand with the 5BTR receptor showed the presence of important amino 
acid interactions, namely Glu(E)230–Arg(R)446, 65.80%; Arg(R)234–
Asp(D)475, 70.9%; Arg(R)234–His(H)473, 33.3%; and Arg234–Val459, 
4.9% (Fig. 10). The results of this analysis indicate that the SIRT1 
activator is showed by hydrogen bond interactions between Glu230 and 
Arg234 (allosteric region) with Arg446, Val459, His473, and Asp475 
(catalytic region) which are close to the bound substrate region.
Free energy calculation (ΔG)
The result of the ΔG bond energy calculated from the molecular docking 
with AutoDock4Zn was then recalculated to determine the free bonding 
energy from the 4TO compound with SIRT1 PDB IDs 4ZZI, 4ZZJ, 4ZZH, 
and 5BTR using the MM-GB(PB)SA method, with simulation dynamics 
carried out for 50 ns. This was performed to ensure that the bond energy 
was more selective [23], and the energy value of the 4TO ligand bond 
with 4ZZJ receptor using the MMGBSA method was calculated, while 
MMPBSA measured bond energy on simulation dynamics for 50 ns.
Fig. 7: Root mean square fluctuation complex of 4TO ligand with 4ZZI, 4ZZJ, 4ZZH, and 5BTR macromolecules
Fig. 8: Root mean square fluctuation of the backbone atoms from 4ZZI, 4ZZJ, 4ZZH, and 5BTR complex with 4TO in the allosteric domain
Fig. 9: Snapshot dynamic simulation of 4TO interaction with 4ZZI 
and 4ZZH receptors, whereas Glu230 residue (allosteric region) 
with Arg446 (catalytic region) did not show hydrogen bonding
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The calculation of the compound complex of 4TO ligand crystal with peptide 
Zn: NAD+:4ZZJ found a value of MMGBSA (ΔGtotal) = −31.4729 kcal/mol, 
ΔGtotal = ΔGgas + ΔGsolv = −51.2942 + 19.8212 = −31.479 kcal/mol. Fig. 11 
shows an example of the calculation. Fig. 12 shows the overall results.
The 4TO:Zn:4ZZI bond energy was measured for 50 ns at a temperature 
of 300 K, which showed a range of bond energy values as follows: 
MMGBSA ∆G =1.9479 kcal/mol (−28.4461–−26.4982) and MMPBSA 
∆G = 1.4592 kcal/mol (−30.0343–−28.5751). The bond energy of 
4TO:peptide:Zn: NAD+:4ZZJ showed a range of bonding energy values 
as follows: MMGBSA ∆G = 4.7973 kcal/mol (−31.4729–−26.6756) and 
MMPBSA ∆G = 4.1432 kcal/mol (−32.6292–−28486). The 4TO:Zn:4ZZH 
bond energy indicates the range of bond energy enzymes as follows: 
MMGBSA ∆G = 10.9523 kcal/mol (−36.2616–−25.3093) and MMPBSA 
∆G = 10.8905 kcal/mol (−37.4334–−26.5429). The bond energy of 
4TO:Zn:5BTR:Ac:peptide showed a range of energy values as follows: 
MMGBSA ∆G = 10.56 kcal/mol (−40.6255–−30.0653) and MMPBSA 
∆G = 8.6762 kcal/mol (−34.6713–−25.9951). The results obtained from 
Fig. 10: Hydrogen bond strength (% occupancy) of important amino acid interactions in the complex of 4TO:4ZZJ and 4TO:5BTR
Fig. 11: Calculation of free bonding energy (MMGBSA) in 4TO: peptide:Zn: NAD+:4ZZJ complex. The calculation of the compound complex 
of 4TO ligand crystal with peptide: Zn:NAD+:4ZZJ found a value of MMGBSA (ΔGtotal) = −31.4729 kcal/mol, ΔGtotal = ΔGgas + ΔGsolv = 
−51.2942 + 19.8212 = −31.479 kcal/mol
Int J App Pharm, Vol 11, Special Issue 1, 2019
 Azminah et al. 
 The 3rd International Conference on Global Health (ICGH), Universitas Indonesia, Bali, Indonesia 244
the four different receptors (4ZZI, 4ZZJ, 4ZZH, and 5BTR) showed that 
the strength of the 4TO bond to 5BTR was stronger than that of the 
other receptors because the receptor form was more closed. A small 
difference in MM-GB(PB)SA range values was seen in the interaction 
between 4TO:Zn:4ZZI.
CONCLUSIONS
The present study describes an in silico study of SIRT1 bond interaction 
using a simulation approach of molecular dynamics over 50 ns using the 
Amber program. Analysis of activator ligand (4TO) binding to the SIRT1 
receptor (PDB IDs 4ZZJ and 5BTR) showed selectivity of the ligand by 
marked hydrophobic bond features on Leu206, Ile223, Asn226, Ile227, 
and Glu230 of the 4ZZJ and 5BTR receptors.
Hydrogen bond interactions between Glu230 and Arg234 (allosteric 
regions) with Arg446, Val459, His473, and Asp475 (catalytic areas) 
ensured that they became close to the bounding substrate area. The 
bond energy values obtained for 4TO interacting with 4ZZJ using the 
MM-GB(PB)SA calculation using AMBER were as follows: MMGBSA 
ΔG = −31.4729–−26.675 and MMPBSA ΔG = −32.6292–−28.486. The 
bond energy values of the 4TO interaction with 5BTR were as follows: 
MMGBSA ∆G = −40.6255–−30.0653 and MMPBSA ∆G = −34.6713–
−25.9951. These results are important for drug discovery and 
development as they give insight into target interaction of the bonds to 
the more selective SIRT1 activator [24-26].
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Fig. 12: Results of the 4TO bond energy with 4ZZI, 4ZZJ, 4ZZH, and 5BTR receptors using the MMGBSA and MMPBSA method for 50 ns
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SUPPLEMENTAL FIGURE
Supplemental Fig. 2: Molecular docking of the 1NS compound (SIRT1 inhibitor) as a negative control in the allosteric site
Supplemental Fig. 1: (A) (i) Visualization of 4ZZI. (ii) The structure of the 4TO:4ZZI complex shown as a mesh surface image generated by 
CHIMERA (hydrophilic, blue; hydrophobic, orange). (iii) Three-dimensional image generated using LigandScout. (B) (i) Visualization of 
4ZZJ. (ii) The structure of the 4TO:4ZZJ complex shown as a mesh surface image generated by CHIMERA (hydrophilic, blue; hydrophobic, 
orange). (iii) Three-dimensional image generated using LigandScout. (C) (i) Visualization of 4ZZH. (ii) The structure of the 4TO:4ZZH 
complex shown as a mesh surface image generated by CHIMERA (hydrophilic, blue; hydrophobic, orange). (iii) Three-dimensional image 
generated using LigandScout. (D) (i) Visualization of 5BTR. (ii) The structure of the resveratrol:4ZZJ complex shown as a mesh surface 
image generated by CHIMERA (hydrophilic, blue; hydrophobic, orange). (iii) Hydrogen bond interaction at the allosteric region
